Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7669421 | 0.98 | GBA1 (0.59) | GBA1SLC6A4SIGMAR1SLC18A3ITGB3 | |
| SCHEMBL3358034 | 0.95 | GBA1 (0.59) | GBA1SLC6A4SIGMAR1ITGB3ITGA2B | |
| SCHEMBL11537058 | 0.93 | GBA1 (0.58) | GBA1SLC6A4SIGMAR1ITGB3ITGA2B | |
| SCHEMBL2241250 | 0.89 | GBA1 (0.66) | GBA1SLC6A4 | |
| Hydrochloric Acid SCHEMBL1532936 | 0.87 | GBA1 (0.63) | GBA1SLC6A4 | |
| SCHEMBL31490479 | 0.86 | SLC18A3 (0.57) | SLC18A3HRH3 | |
| SCHEMBL12735855 | 0.85 | MEN1 (0.59) | GBA1SIGMAR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL1532763 | 0.84 | MEN1 (0.57) | GBA1SIGMAR1ITGB3ITGA2BHRH3 | |
| SCHEMBL7103234 | 0.82 | SLC18A3 (0.62) | SIGMAR1SLC18A3 | |
| SCHEMBL26629763 | 0.82 | SLC18A3 (0.58) | SIGMAR1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117393-A1 | ETCHING AGENT COMPOSITION AND ETCHING METHOD USING THE SAME | KCTECH CO., LTD. (KR) | 2026-04-30 | — | — | US | claimed |
| CN-116768826-B | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2025-05-27 | — | — | CN | claimed |
| CN-115466189-B | Purification method of amino acid and derivative thereof | 安徽普利药业有限公司 | 2024-08-30 | — | — | CN | claimed |
| CN-116768826-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2023-09-19 | — | — | CN | claimed |
| CN-115466189-A | Preparation and purification method of amino acid and derivatives thereof | 安徽普利药业有限公司 | 2022-12-13 | — | — | CN | claimed |
| EP-0012643-B1 | 1-PHENYL-3-(4-PIPERIDYL)-PROPAN-1-ONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM | PHARMUKA LABORATOIRES (FR) | 1982-02-17 | — | — | EP | claimed |
| US-4294841-A | ANTIARRHYTHMIA AGENTS | PHARMINDUSTRIE (FR) | 1981-10-13 | — | — | US | claimed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | claimed |
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20260117393-A1 | ETCHING AGENT COMPOSITION AND ETCHING METHOD USING THE SAME | KCTECH CO., LTD. (KR) | 2026-04-30 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-4136180-A | HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS | PFIZER INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4062960-A | Hypolipidemic alkenesulfonamides | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637494-B2 | Method for producing peptide containing non-natural amino acid | MRPL21, RPL21, RPL30 | GBA1 4499/4885SLC6A4 4434/4885SIGMAR1 3101/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | GBA1 4076/4885SLC6A4 4849/4885SIGMAR1 4837/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | GBA1 2500/4885SLC6A4 2004/4885SIGMAR1 3154/4885 |
| US-20260117393-A1 | ETCHING AGENT COMPOSITION AND ETCHING METHOD USING THE SAME | HCN4, HAO2, ASIC1 | GBA1 2642/4885SLC6A4 665/4885SIGMAR1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.